Pandemic Darlings The pandemic economy, in original documents
Home Source documents CureVac N.V., Form 6-K, For the month of January 2026

CureVac N.V., Form 6-K, For the month of January 2026

Summary

A Form 6-K report of CureVac N.V. for the month of January 2026, stating that on January 6, 2026 CureVac completed the previously announced post-offer reorganization in connection with BioNTech SE's exchange offer for all outstanding CureVac common shares. Under the reorganization, BioNTech became the sole owner of all of CureVac's business operations, CureVac Merger B.V. succeeded CureVac by merger, and no public shareholders continued to hold CureVac shares. CureVac also asked the Nasdaq Global Market to suspend trading and to file a Form 25 with the SEC to delist and deregister the shares under Section 12(b) of the Securities Exchange Act of 1934, with the delisting expected to be effective on January 16, 2026. CureVac Merger then intends to file a Form 15 to terminate registration under Section 12(g) and suspend reporting obligations, with deregistration expected 90 days thereafter.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

On January 6, 2026, CureVac N.V. (“CureVac”) completed the previously announced post-offer
reorganization in connection with BioNTech SE’s (“BioNTech”) exchange offer for all outstanding common shares, par value €0.12 per share, of CureVac (the “CureVac Shares”). Pursuant to the post-offer
reorganization, BioNTech became the sole owner of all of CureVac’s business operations, CureVac Merger B.V. (“CureVac Merger”) succeeded CureVac by merger, and no public shareholders continued to hold any CureVac Shares.

On January 6, 2026, CureVac notified the Nasdaq Global Market (“Nasdaq”) of the completion of the post-offer reorganization and requested
that Nasdaq (i) suspend trading of the CureVac Shares on Nasdaq before the opening of trading on January 6, 2026 and (ii) file a Notification of Removal from Listing on Form 25 (the “Form 25”) with the Securities and
Exchange Commission (the “SEC”) to delist the CureVac Shares from Nasdaq and deregister the CureVac Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Upon the
effectiveness of the Form 25, the CureVac Shares will no longer be listed on Nasdaq. CureVac expects the delisting to be effective on January 16, 2026.

In addition, after effectiveness of the Form 25, CureVac Merger intends to file with the SEC a Certification and Notice of Termination of Registration on Form
15 requesting the termination of registration of the CureVac Shares under Section 12(g) of the Exchange Act and the suspension of CureVac’s reporting obligations under Sections 13 and 15(d) of the Exchange Act with respect to the CureVac
Shares. Immediately upon the filing of Form 15, CureVac’s legal obligation to file certain reports under the Exchange Act will be suspended, and deregistration is expected to become effective 90 days thereafter.

File and source

File
d24025d6k.htm.html
Size
10,784 bytes
SHA-256
5bdd5301d53174315f86b829d4084d6ba55a7e6225bab4224c5352bc1f1fa883
Our copy
d24025d6k.htm.html
Original
www.sec.gov
Back to top